Compare Novo Nordisk A/S (NVO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Waste Management, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Waste Management, Inc. trades at $233.18 (market cap $96.00B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Waste Management, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | WM | |
|---|---|---|
Market Cap | $220.53B | $96.00B |
Sector | Health | Industrials |
52-Week High | $71.70 | $246.51 |
52-Week Low | $35.29 | $196.77 |
Enterprise Value | $239.49B | $118.73B |
Dividend Yield | 3.63% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
WM (Waste Management) trades at $233.18, down 2.56% on the day, but remains near its 52-week high of $248.13. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal steady revenue growth to $25.20 billion in 2025 and a robust 10.99% net income margin. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 results missed. Analyst sentiment is positive with a consensus buy rating and $263.57 price target, supported by a reliable dividend and strong cash flow from operations of $6.04 billion.
Outlook: WM's dominant market position, pricing power, and renewable energy initiatives support long-term growth, but high debt levels and competitive pressures pose risks. The stock offers value for income and growth investors, with potential upside to analyst targets if execution remains solid amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
